ArticleLasers in medical science2026
Photobiomodulation therapy reduces diabetic periodontal damage through modulation of macrophage metabolism and functions.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Diabetes mellitus disrupts macrophage function and immune homoeostasis, thereby increasing susceptibility toward periodontitis. PBMT shows emerging potential in oral rehabilitation. However, it remains underexplored for targeting diabetes-associated periodontal complications. This study aimed to investigate the biomodulatory effects of PBMT on hyperglycaemia-associated macrophage dysfunction, metabolic disorders, and periodontal tissue impairment. Immortalized bone marrow-derived macrophages undergoing glucose transition and streptozotocin-induced diabetic mice received PBMT (980 nm, 3 J/cm²), insulin, or combined therapy. Pharmacological inhibition using specific inhibitors targeting FOXO1, AKT, and ERK was employed to elucidate signaling mechanisms. Cellular functions were assessed through Transwell migration, phagocytosis, and senescence-associated β-galactosidase staining. Metabolic parameters were evaluated via western blotting, ATP/LDH assays, and immunostaining. Tissue morphology was analyzed using micro-CT and H&E staining. PBMT enhanced macrophage phagocytosis, migration, and anti-inflammatory phenotype. The combined PBMT-insulin therapy demonstrated superior efficacy in restoring periodontal architecture compared to monotherapy. Mechanistically, PBMT attenuated FOXO1 hyperactivation primarily through MEK/ERK signaling. PBMT effectively counteracted hyperglycemia-induced metabolic dysregulation, restored macrophage function and phenotype, and mitigated subsequent periodontal tissue damage. The MEK/ERK/FOXO1 signalling pathway may represent a novel mechanism underlying the benefits of PBMT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.